{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"115"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"Disease Control (DC) is defined as complete or partial response, or disease stabilisation at 24 weeks (+/- 10 days). Patients with no available scan at this time period, but with scan performed before 24 weeks - 10 days and scan performed after 24 weeks + 10 days showing disease control, will be considered as disease control.","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy population (Intention-To-Treat cohort of all randomised patients)","reportingStatus":"POSTED","timeFrame":"From randomization to 24 weeks; participants assessed for treatment response status at 24 weeks.","title":"Disease Control (DC) at 24 Weeks","type":"SECONDARY","unitOfMeasure":"Participants"}